PORTFOLIO

RECENT NEWS & EVENTS

March 6, 2014 Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
» Press Release | Company News

 

March 5, 2014 bluebird bio Reports Fiscal Year End 2013 Financial Results
» Press Release | Company News

 

Launching & Building Transforming Companies Together

"Over the last 12 months, I have seen a dramatic increase in the active collaboration between leaders of the Third Rock portfolio companies. I am able to tap into my peers for perspectives on everything from compensation to recruitment, and they've tapped into Agios for insights into partnering and financing. By better connecting Third Rock's portfolio company leadership teams to each other, we are learning from one another and helping each other navigate the company building process."

David Schenkein, M.D.
Chief Executive Officer of
Agios Pharmaceuticals

Third Rock Ventures was founded in 2007 with the mission to launch transforming companies. We set out to build a different firm – a firm that was squarely focused on launching exceptional healthcare companies with passionate entrepreneurs, working in areas of disruptive science and medicine to make a difference in the lives of patients.


We are not just launching new healthcare companies - we are rapidly growing them, advancing pipelines to the clinic and developing new products. In just six short years, and during a period of time when early stage investing has been in flux, we have successfully raised more than $1.3 billion and invested in more than 31 companies to accomplish this mission. We truly believe that nothing is impossible.


We take investments in our companies and our people seriously, as we strive to be the best business partners in the world. By working closely with the scientific and business communities, we seek to identify the most promising opportunities for the future of medicine and then build the team and company structure to make this visionary science a business reality. Our portfolio companies are formed around disruptive areas of science and medicine and the convergence of technology and genomics, and many have been developed as part of collaborations with big pharma and big biotech. Collaborative company building is the future, and Third Rock and its portfolio companies are at the forefront of this paradigm shift with early-stage yet highly valued strategic partnerships.


Our approach is bold, our thinking is outside-of-the-box and we apply the same innovative spirit to our deal-making as we do to our companies' science. Together, this approach is designed to achieve our ultimate goal – launching and building transforming companies that make a difference for patients through breakthroughs in medicine.